Activation of cannabinoid receptor 2 inhibits experimental cystitis

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 304, Issue 10, 2013, Pages

  Wang, Zun Yi ^a   Wang, Peiqing ^a   Bjorling, Dale E ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Cannabinoid receptor 2; Cystitis; GP1a; Hyperalgesia; Mice

Indexed keywords

6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; CANNABINOID 2 RECEPTOR; CANNABINOID 2 RECEPTOR AGONIST; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; N (PIPERIDIN 1 YL) 1 (2,4 DICHLOROPHENYL) 1,4 DIHYDRO 6 METHYLINDENO[1,2 C]PYRAZOLE 3 CARBOXAMIDE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; UO 126;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; CYSTITIS; DISEASE SEVERITY; DRUG EFFECT; ENZYME PHOSPHORYLATION; FEMALE; HYPERALGESIA; INFLAMMATORY CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; UROTHELIUM;

CANNABINOID RECEPTOR 2; CYSTITIS; GP1A; HYPERALGESIA; MICE;

ACROLEIN; ANIMALS; CANNABINOID RECEPTOR AGONISTS; CANNABINOID RECEPTOR ANTAGONISTS; CYSTITIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HYPERALGESIA; INDENES; INDOLES; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASES; PAIN MEASUREMENT; PYRAZOLES; RECEPTOR, CANNABINOID, CB2; SEVERITY OF ILLNESS INDEX;

EID: 84878662589     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00585.2012     Document Type: Article

References (78)

1. Alagiri M, Chottiner S, Ratner V, Slade D, Hanno PM. Interstitial cystitis: unexplained associations with other chronic disease and pain syndromes. Urology 49 (Suppl 5A): 52-57, 1997.
2. Anand P, Whiteside G, Fowler CJ, Hohmann AG. Targeting CB2 receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev 60: 255-266, 2009.
3. Barutta F, Piscitelli F, Pinach S, Bruno G, Gambino R, Rastaldi MP, Salvidio G, Di Marzo V, Cavallo Perin P, Gruden G. Protective role of cannabinoid receptor type 2 in a mouse model of diabetic nephropathy. Diabetes 60: 2386-2396, 2011.
4. Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23:1530-1538, 2006.
5. Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, Nyberg L, Clemens JQ. Prevalence of symptoms of bladder pain syndrome/ interstitial cystitis among adult females in the United States. J Urol 186: 540-544, 2011.
6. Birder LA. Urothelial signaling. Handb Exp Pharmacol 202: 207-231, 2011.
7. Bon K, Lanteri-Minet M, Michiels JF, Menetrey D. Cyclophosphamide cystitis as a model of visceral pain in rats: a c-fos and Krox-24 study at telencephalic levels, with a note on pituitary adenylate cyclase activating polypeptide (PACAP). Exp Brain Res 122: 165-174, 1998.
8. Cervero F, Laird JM. Understanding the signaling and transmission of visceral nociceptive events. J Neurobiol 61: 45-54, 2004.
9. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 410: 37-40, 2001.
10. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53: 55-63, 1999.
11. Chung CW, Zhang QL, Qiao LY. Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis. J Biol Chem 285: 4206-4212, 2010.
12. Clayton N, Marshall FH, Bountra C, O'Shaughnessy CT. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. Pain 96: 253-260, 2002.
13. Conklin DJ, Haberzettl P, Lesgards JF, Prough RA, Srivastava S, Bhatnagar A. Increased sensitivity of glutathione S-transferase P-null mice to cyclophosphamide-induced urinary bladder toxicity. J Pharmacol Exp Ther 331: 456-469, 2009.
14. Corrow KA, Vizzard MA. Phosphorylation of extracellular signal-regulated kinases in urinary bladder in rats with cyclophosphamide-induced cystitis. Am J Physiol Regul Integr Comp Physiol 293: R125-R134, 2007.
15. Cox PJ. Cyclophosphamide cystitis-identification of acrolein as the causative agent. Biochem Pharmacol 28: 2045-2049, 1979.
16. Cruz CD, Cruz F. The ERK 1 and 2 pathway in the nervous system: from basic aspects to possible clinical applications in pain and visceral dysfunction. Curr Neuropharmacol 5: 244-252, 2007.
17. Demuth DG, Molleman A. Cannabinoid signalling. Life Sci 78: 549-563, 2006.
18. Dong C, Davis RJ, Flavell RA. MAP kinases in the immune response. Annu Rev Immunol 20: 55-72, 2002.
19. Elmes SJ, Winyard LA, Medhurst SJ, Clayton NM, Wilson AW, Kendall DA, Chapman V. Activation of CB1 and CB2 receptors attenuates the induction and maintenance of inflammatory pain in the rat. Pain 118: 327-335, 2005.
20. Erickson DR, Davies MF. Interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 9: 174-183, 1998.
21. Fernández-López D, Pazos MR, Tolón RM, Moro MA, Romero J, Lizasoain I, Martínez-Orgado J. The cannabinoid agonist WIN55212 reduces brain damage in an in vivo model of hypoxic-ischemic encephalopathy in newborn rats. Pediatr Res 62: 255-260, 2007.
22. Franklin JM, Vasiljevik T, Prisinzano TE, Carrasco GA. Cannabinoid 2 receptor- and beta arrestin 2-dependent upregulation of serotonin 2A receptors. Eur Neuropsychopharmacol In press.
23. Galan A, Cervero F, Laird JM. Extracellular signaling-regulated kinase-1 and -2 (ERK 1/2) mediate referred hyperalgesia in a murine model of visceral pain. Brain Res Mol Brain Res 116: 126-134, 2003.
24. Galan A, Lopez-Garcia JA, Cervero F, Laird JM. Activation of spinal extracellular signaling-regulated kinase-1 and -2 by intraplantar carrageenan in rodents. Neurosci Lett 322: 37-40, 2002.
25. Girard BM, Tompkins JD, Parsons RL, May V, Vizzard MA. Effects of CYP-induced cystitis on PACAP/VIP and receptor expression in micturition pathways and bladder function in mice with overexpression of NGF in urothelium. J Mol Neurosci 48: 730-743, 2012.
26. Gratzke C, Streng T, Park A, Christ G, Stief CG, Hedlund P, Andersson KE. Distribution and function of cannabinoid receptors 1 and 2 in the rat, monkey and human bladder. J Urol 181:1939-1948, 2009.
27. Gratzke C, Streng T, Stief CG, Downs TR, Alroy I, Rosenbaum JS, Andersson KE, Hedlund P. Effects of cannabinor, a novel selective cannabinoid 2 receptor agonist, on bladder function in normal rats. Eur Urol 57:1093-1100, 2010.
28. Gratzke C, Streng T, Stief CG, Alroy I, Limberg BJ, Downs TR, Rosenbaum JS, Hedlund P, Andersson KE. Cannabinor, a selective cannabinoid-2 receptor agonist, improves bladder emptying in rats with partial urethral obstruction. J Urol 185:731-736, 2011.
29. Guindon J, Hohmann AG. Cannabinoid CB2 receptors: a therapeutic target for the treatment of inflammatory and neuropathic pain. Br J Pharmacol 153: 319-334, 2008.
30. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG. Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150: 153-163, 2007.
31. Hanus L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci USA 96: 14228-14233, 1999.
32. Hayn MH, Ballesteros I, de Miguel F, Coyle CH, Tyagi S, Yoshimura N, Chancellor MB, Tyagi P. Functional and immunohistochemical characterization of CB1 and CB2 receptors in rat bladder. Urology 72: 1174-1178, 2008.
33. Horváth B, Magid L, Mukhopadhyay P, Bátkai S, Rajesh M, Park O, Tanchian G, Gao RY, Goodfellow CE, Glass M, Mechoulam R, Pacher P. A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol 165: 2462-2478, 2012.
34. Hsieh GC, Pai M, Chandran P, Hooker BA, Zhu CZ, Salyers AK, Wensink EJ, Zhan C, Carroll WA, Dart MJ, Yao BB, Honore P, Meyer MD. Central and peripheral sites of action for CB2 receptor mediated analgesic activity in chronic inflammatory and neuropathic pain models in rats. Br J Pharmacol 162: 428-440, 2011.
35. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP, Vanderah TW, Lai J, Porreca F, Makriyannis A, Malan TP Jr. Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533, 2003.
36. Ibrahim MM, Rude ML, Stagg NJ, Mata HP, Lai J, Vanderah TW, Porreca F, Buckley NE, Makriyannis A, Malan TP Jr. CB2 cannabinoid receptor mediation of antinociception. Pain 122: 36-42, 2006.
37. Ji RR, Gereau 4th RW, Malcangio M, Strichartz GR. MAP kinase and pain. Brain Res Rev 60: 135-148, 2009.
38. Kinsey SG, Mahadevan A, Zhao B, Sun H, Naidu PS, Razdan RK, Selley DE, Imad Damaj M, Lichtman AH. The CB2 cannabinoid receptor-selective agonist O-3223 reduces pain and inflammation without apparent cannabinoid behavioral effects. Neuropharmacology 60: 244-251, 2011.
39. Klegeris A, Bissonnette CJ, McGeer PL. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid- type CB2 receptor. Br J Pharmacol 139: 775-786, 2003.
40. Klinger MB, Dattilio A, Vizzard MA. Expression of cyclooxygenase-2 in urinary bladder in rats with cyclophosphamide-induced cystitis. Am J Physiol Regul Integr Comp Physiol 293: R677-R685, 2007.
41. Klinger MB, Sacks S, Cervero F. A role for extracellular signalregulated kinases 1 and 2 in the maintenance of persistent mechanical hyperalgesia in ovariectomized mice. Neuroscience 172: 483-493, 2011.
42. Laird JM, Souslova V, Wood JN, Cervero F. Deficits in visceral pain and referred hyperalgesia in Nav1.8 (SNS/PN3)-null mice. J Neurosci 22: 8352-8356, 2002.
43. Lozano-Ondoua AN, Wright C, Vardanyan A, King T, Largent-Milnes TM, Nelson M, Jimenez-Andrade JM, Mantyh PW, Vanderah TW. A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. Life Sci 86: 646-653, 2010.
44. Lozano-Ondoua A, Hanlon K, Symons A, Largent-Milnes T, Havelin J, Ferland 3rd H, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom A, Jimenez-Andrade J, King T, Porreca F, Nelson M, Mantyh P, Vanderah T. Disease modification of breast cancerinduced bone remodeling by cannabinoid 2 receptor agonists. J Bone Miner Res 28: 92-107, 2012.
45. Malan TP Jr, Ibrahim MM, Deng H, Liu Q, Mata HP, Vanderah T, Porreca F, Makriyannis A. CB2 cannabinoid receptor-mediated peripheral antinociception. Pain 93: 239-245, 2001.
46. Malan TP Jr, Ibrahim MM, Lai J, Vanderah TW, Makriyannis A, Porreca F. CB2 cannabinoid receptor agonists: pain relief without psychoactive effects? Curr Opin Pharmacol 3: 62-67, 2003.
47. Martin A, Garcia-Ovejero D, Molina-Holgado E. The endocannabinoid 2-arachidonoylglycerol reduces lesion expansion and white matter damage after spinal cord injury. Neurobiol Dis 38: 304-312, 2010.
48. May V, Vizzard MA. Bladder dysfunction and altered somatic sensitivity in PACAP-/- mice. J Urol 183: 772-779, 2010.
49. Merriam FV, Wang ZY, Guerios SD, Bjorling DE. Cannabinoid receptor 2 is increased in acutely and chronically inflamed bladder of rats. Neurosci Lett 445: 130-134, 2008.
50. Merriam FV, Wang ZY, Hillard CJ, Stuhr KL, Bjorling DE. Inhibition of fatty acid amide hydrolase suppresses referred hyperalgesia induced by bladder inflammation. BJU Int 108: 1145-1149, 2011.
51. Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J Mol Cell Cardiol 46: 612-620, 2009.
52. Mukhopadhyay P, Rajesh M, Horváth B, Bátkai S, Park O, Tanchian G, Gao RY, Patel V, Wink DA, Liaudet L, Haskó G, Mechoulam R, Pacher P. Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med 50: 1368-1381, 2011.
53. Murineddu G, Lazzari P, Ruiu S, Sanna A, Loriga G, Manca I, Falzoi M, Dessì C, Curzu MM, Chelucci G, Pani L, Pinna GA. Tricyclic pyrazoles, 4: synthesis and biological evaluation of analogs of the robust and selective CB2 cannabinoid ligand 1-(2′,4′-dichlorophenyl)-6-methyl- N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide. J Med Chem 49: 7502-7512, 2006.
54. Nackley AG, Makriyannis A, Hohmann AG. Selective activation of cannabinoid CB2 receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience 119: 747-757, 2003.
55. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG. Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574, 2004.
56. Ofek O, Karsak M, Leclerc N, Fogel M, Frenkel B, Wright K, Tam J, Attar-Namdar M, Kram V, Shohami E, Mechoulam R, Zimmer A, Bab I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci USA 103: 696-701, 2006.
57. Palazuelos J, Aguado T, Pazos MR, Julien B, Carrasco C, Resel E, Sagredo O, Benito C, Romero J, Azcoitia I, Fernández-Ruiz J, Guzmán M, Galve-Roperh I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington's disease excitotoxicity. Brain 132: 3152-3164, 2009.
58. Patel KD, Davison JS, Pittman QJ, Sharkey KA. Cannabinoid CB2 receptors in health and disease. Curr Med Chem 17: 1393-1410, 2010.
59. Qiao LY, Gulick MA. Region-specific changes in the phosphorylation of ERK1/2 and ERK5 in rat micturition pathways following cyclophosphamide- induced cystitis. Am J Physiol Regul Integr Comp Physiol 292: R1368-R1375, 2007.
60. Quartilho A, Mata HP, Ibrahim MM, Vanderah TW, Porreca F, Makriyannis A, Malan TP Jr. Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology 99: 955-960, 2003.
61. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall DA, Chapman V. Inhibitory effects of CB1 and CB2 receptor agonists on responses of DRG neurons and dorsal horn neurons in neuropathic rats. Eur J Neurosci 22: 371-379, 2005.
62. Schuh K, Pahl A. Inhibition of the MAP kinase ERK protects from lipopolysaccharide-induced lung injury. Biochem Pharmacol 77: 1827-1834, 2009.
63. Steffens S, Veillard NR, Arnaud C, Pelli G, Burger F, Staub C, Karsak M, Zimmer A, Frossard JL, Mach F. Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434: 782-786, 2003.
64. Storr MA, Keenan CM, Zhang H, Patel KD, Makriyannis A, Sharkey KA. Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis 15: 1678-1685, 2009.
65. Strittmatter F, Gandaglia G, Benigni F, Bettiga A, Rigatti P, Montorsi F, Gratzke C, Stief C, Colciago G, Hedlund P. Expression of fatty acid amide hydrolase (FAAH) in human, mouse, and rat urinary bladder and effects of FAAH inhibition on bladder function in awake rats. Eur Urol 61: 98-106, 2012.
66. Studeny S, Cheppudira BP, Meyers S, Balestreire EM, Apodaca G, Birder LA, Braas KM, Waschek JA, May V, Vizzard MA. Urinary bladder function and somatic sensitivity in vasoactive intestinal polypeptide (VIP)-/- mice. J Mol Neurosci 36: 175-187, 2008.
67. Tripp DA, Nickel JC, Wong J, Pontari M, Moldwin R, Mayer R, Carr LK, Doggweiler R, Yang CC, Mishra N, Nordling J. Mapping of pain phenotypes in female patients with bladder pain syndrome/interstitial cystitis and controls. Eur Urol 62: 1188-1194, 2012.
68. Tschöp J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, Dattilo J, Lentsch AB, Tschöp MH, Caldwell CC. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 183: 499-505, 2009.
69. Tyagi V, Philips BJ, Su R, Smaldone MC, Erickson VL, Chancellor MB, Yoshimura N, Tyagi P. Differential expression of functional cannabinoid receptors in human bladder detrusor and urothelium. J Urol 181: 1932-1938, 2009.
70. Tyagi P, Tyagi V, Yoshimura N, Chancellor M. Functional role of cannabinoid receptors in urinary bladder. Indian J Urol 26: 26-35, 2010.
71. Vera PL, Wolfe TE, Braley AE, Meyer-Siegler KL. Thrombin induces macrophage migration inhibitory factor release and upregulation in urothelium: a possible contribution to bladder inflammation. PLoS One 5: e15904, 2010.
72. Vizzard MA. Neurochemical plasticity and the role of neurotrophic factors in bladder reflex pathways after spinal cord injury. Prog Brain Res 152: 97-115, 2006.
73. Walczak JS, Cervero F. Local activation of cannabinoid CB2 receptors in the urinary bladder reduces the inflammation-induced sensitization of bladder afferents. Mol Pain 7: 31, 2011.
74. Wang ZY, Wang P, Merriam FV, Bjorling DE. Lack of TRPV1 inhibits cystitis-induced increased mechanical sensitivity in mice. Pain 139: 158-167, 2008.
75. Wang ZY, Wang P, Bjorling DE. Role of mast cells and proteaseactivated receptor-2 in cyclooxygenase-2 expression in urothelial cells. Am J Physiol Regul Integr Comp Physiol 297: R1127-R1135, 2009.
76. Wang ZY, Bjorling DE. Tumor necrosis factor-α induces expression and release of interleukin-6 by human urothelial cells. Inflamm Res 60: 525-532, 2011.
77. White JP, Cibelli M, Fidalgo AR, Nagy I. Extracellular signal-regulated kinases in pain of peripheral origin. Eur J Pharmacol 650: 8-17, 2011.
78. Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci 19: 4644-4653, 1999.